Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 11/20 | 0.43 |
| ▸ | RBPJ | Q06330 | 7/20 | 0.43 |
| ▸ | NOTCH3 | Q9UM47 | 4/20 | 0.39 |
| ▸ | CCKBR | P32239 | 8/20 | 0.39 |
| ▸ | CCKAR | P32238 | 7/20 | 0.39 |
| ▸ | CBLB | Q13191 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29692189 | 1.00 | NOTCH1 (0.43) | NOTCH1RBPJNOTCH3CCKBRCCKAR | |
| SCHEMBL23013261 | 1.00 | NOTCH1 (0.43) | NOTCH1RBPJNOTCH3CCKBRCCKAR | |
| SCHEMBL29692172 | 0.89 | NOTCH1 (0.40) | NOTCH1RBPJNOTCH3CCKBRCCKAR | |
| SCHEMBL23013980 | 0.89 | NOTCH1 (0.40) | NOTCH1RBPJNOTCH3CCKBRCCKAR | |
| SCHEMBL23013097 | 0.85 | NOTCH1 (0.46) | NOTCH1RBPJNOTCH3CCKBRCCKAR | |
| SCHEMBL29692157 | 0.84 | CBLB (0.45) | NOTCH1RBPJCCKBRCCKARCBLB | |
| SCHEMBL23013850 | 0.84 | CBLB (0.45) | NOTCH1RBPJCCKBRCCKARCBLB | |
| SCHEMBL29692119 | 0.83 | NOTCH1 (0.41) | NOTCH1RBPJNOTCH3CCKBRCCKAR | |
| SCHEMBL23023802 | 0.83 | NOTCH1 (0.42) | NOTCH1RBPJNOTCH3CCKBRCCKAR | |
| SCHEMBL23013788 | 0.83 | NOTCH1 (0.42) | NOTCH1RBPJNOTCH3CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227507-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2025-02-18 | — | — | US | claimed |
| US-20220306639-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-09-29 | — | — | US | claimed |
| EP-4017856-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2022-06-29 | — | — | EP | claimed |
| WO-2021032992-A1 | PHARMACEUTICAL COMPOUNDS | ReViral Limited (GB) | 2021-02-25 | — | — | WO | claimed |
| US-12227507-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-114555604-B | Pharmaceutical compounds | 辉瑞公司 | 2024-11-15 | — | — | CN | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220324873-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220306639-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-09-29 | — | — | US | disclosed |
| EP-4017856-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021032992-A1 | PHARMACEUTICAL COMPOUNDS | ReViral Limited (GB) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227507-B2 | Pharmaceutical compounds | CHRNA6, GABRA6, CHRNA7 | NOTCH1 4608/4885RBPJ 1110/4885NOTCH3 4553/4885 |
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | NOTCH1 4652/4885RBPJ 1150/4885NOTCH3 4645/4885 |
| US-20220306639-A1 | PHARMACEUTICAL COMPOUNDS | CHRNA6, GABRA6, CHRNA7 | NOTCH1 4608/4885RBPJ 1110/4885NOTCH3 4553/4885 |
| US-20220324873-A1 | PHARMACEUTICAL COMPOUNDS | GABRA6, CNR1, CHRNA6 | NOTCH1 4533/4885RBPJ 1335/4885NOTCH3 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.